What is B. Riley’s Estimate for Novavax FY2024 Earnings?

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at B. Riley dropped their FY2024 earnings estimates for Novavax in a research note issued to investors on Thursday, February 20th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($1.83) per share for the year, down from their prior forecast of ($1.41). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s Q4 2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($0.84) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.83.

Novavax Stock Down 3.2 %

NVAX stock opened at $7.17 on Monday. The company has a market cap of $1.15 billion, a PE ratio of -3.17, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The business has a 50-day simple moving average of $8.62 and a 200 day simple moving average of $10.07. Novavax has a 52 week low of $3.81 and a 52 week high of $23.86.

Institutional Trading of Novavax

Several institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in shares of Novavax during the 4th quarter valued at about $27,000. Spire Wealth Management purchased a new position in shares of Novavax during the 4th quarter valued at about $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax during the 4th quarter valued at about $35,000. KBC Group NV raised its holdings in shares of Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 3,917 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Novavax by 38.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Buying and Selling at Novavax

In other Novavax news, Director James F. Young sold 4,600 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total value of $39,008.00. Following the sale, the director now owns 57,160 shares of the company’s stock, valued at $484,716.80. This trade represents a 7.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock valued at $119,641 in the last 90 days. Corporate insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.